In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.
Joshua Zeichner, MD, associate professor of dermatology and director of cosmetic & clinical research in dermatology, Mount Sinai Hospital, New York, discusses the impact of the recent FDA approval of Twyneo (Sol-Gel) for the treatment of acne.
This week’s edition of The Mainstream Patient features stories about purchasing non-toxic sunscreen, biologics for psoriasis, biotin for hair growth, "bacne", plus more.
In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).
In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.
Christopher Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.
This week’s edition of The Mainstream Patient features stories about skin care ingredients to avoid while breastfeeding, psoriatic arthritis management tips, Monistat for hair growth, plus more.
A group of expert panelists gathered to discuss how social media can benefit your practice and how to best use it to your advantage.
This week’s edition of The Mainstream Patient features stories about a new TikTok-inspired acne treatment, skin care ingredient absorption, injectable psoriasis treatments, plus more.
Christopher Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.
The FDA did not meet the PDUFA goal date for abrocitinib (PF-04965842; Pfizer), a potential treatment of moderate to severe atopic dermatitis in adults and adolescents.
The FDA has decided to delay the PDUFA goal date for baricitinib for treatment of adults with moderate to severe atopic dermatitis.
ICYMI, some of this week’s featured content includes practice management tips, SGT-510 for psoriasis, July skin care, plus more.
Looking to get your practice ahead of the rest post-COVID-19? These 10 practical practice management tips will help you jump start your practice into the future.
July marks the 1 year anniversary since the launch of The Cutaneous Connection Podcast. Check out what episodes were the most popular here.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of July.
The introduction of artificial intelligence into dermatology has been met with mixed emotions from the medical community. In this episode, Ade Adamson, MD, MPP, explains the benefits and detriments of the application, accuracy, and potential racial diagnostic bias.
This week’s edition of The Mainstream Patient features stories about eyelid eczema, biologics, jojoba oil for acne, plus more.
ICYMI, some of this week’s featured content includes AI in dermatology, mental health and PsA treatment, AD therapies, at-home keratosis pilaris treatments, plus more.
The introduction of artificial intelligence into dermatology has been met with mixed emotions from the medical community. In this episode, Ade Adamson, MD, MPP, explains the benefits and detriments of the application, accuracy, and potential racial diagnostic bias.
OncoSec Medical Inc. and Merck have entered into a supply and clinical trial agreement for pembrolizumab (Keytruda) and tavokinogene telseplasmid (Tavo) for the potential treatment of late-stage metastatic melanoma.
Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.
Explore what dermatologic drugs the FDA will decide to approve during July 2021.
This week’s edition of The Mainstream Patient features stories about perioral dermatitis, rosacea, forever chemicals in cosmetics, plus more.
ICYMI, some of this week’s featured content includes practice management tips, microneedling for improving skin laxity and fat deposits, nasal papules linked to acne, plus more.
This week’s edition of The Mainstream Patient features stories about skin care texture, scalp acne treatments, sanitizing beauty products, jade rollers, plus more.
ICYMI, some of this week’s featured content includes the newest regulatory updates for cemiplimab for BCC and upadacitinib for PsA. Plus, stories on practice management, webinar recaps, and more.
The European Commission has approved cemiplimab for the treatment of locally advanced or metastatic basal cell carcinoma in adults.
The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.
This week’s edition of The Mainstream Patient features stories about face mapping, benzene contamination in sunscreen, natural retinol, ceramides in skin care, plus more.
